Showing results (501-510 of 1,794) with videos related to

Sort By:
Pageof 180
Mabs|November 10, 2020
Impact of Fc N-linked glycans on in vivo clearance of an immunoglobulin G1 antibody produced by NS0 cell lineJun Kim, Haibin Luo, Wendy White, et al.
Mabs|March 15, 2018
Modification of the kinetic stability of immunoglobulin G by solvent additivesJonas V Schaefer, Erik Sedlák, Florian Kast, et al.
Mabs|March 15, 2018
Isolation and characterization of a monoclonal antibody containing an extra heavy-light chain Fab armDan Boyd, Arpa Ebrahimi, Sarah Ronan, et al.
Mabs|September 7, 2022
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRsAndre A R Teixeira, Sara D'Angelo, M Frank Erasmus, et al.
Mabs|January 15, 2022
Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variantsBo-Seong Jeong, Jeong Seok Cha, Insu Hwang, et al.
Mabs|January 15, 2022
Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capabilityLina Chakrabarti, Raghothama Chaerkady, Junmin Wang, et al.
Mabs|December 29, 2021
Multi-attribute Raman spectroscopy (MARS) for monitoring product quality attributes in formulated monoclonal antibody therapeuticsBingchuan Wei, Nicholas Woon, Lu Dai, et al.
Mabs|December 3, 2021
Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumorsNicola J Mason, Nicholas Chester, Ailian Xiong, et al.
Mabs|February 9, 2021
Combining random mutagenesis, structure-guided design and next-generation sequencing to mitigate polyreactivity of an anti-IL-21R antibodySharon M Campbell, Joseph DeBartolo, James R Apgar, et al.
Mabs|February 9, 2021
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobettersHoUng Kim, Rieke Alten, Fraser Cummings, et al.
Pageof 180